Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Legend Biotech Corporation filings document foreign private issuer current reports, operating updates, governance actions, registration statements, and equity-plan disclosures for a cell therapy biopharmaceutical company. Its Form 6-K reports cover CARVYKTI® preliminary sales information received through the Janssen collaboration, quarterly and annual financial-result releases, corporate presentations, and clinical updates involving the CARTITUDE program and LUCAR-G39D.
The company’s regulatory disclosures also record board appointments and resignations, audit committee leadership, director compensation under restricted share unit plans, and related-party matters involving GenScript. Incorporated Form F-3 and Form S-8 references connect current reports with securities registration and incentive-plan filings, while risk language addresses forward-looking statements, product development, collaboration economics, and commercialization of CAR-T therapies.
Legend Biotech Corp filed an initial insider ownership report for director Robin Meng on Form 3. This filing establishes Meng’s status as a reporting insider but shows no reported transactions or holdings, indicating that only insider status, not trading activity, is being disclosed at this time.
Legend Biotech Corp director Peter Salovey filed an initial ownership report showing 26,766 restricted share units (RSUs) tied to the company’s ordinary shares. Each RSU represents a right to receive one ordinary share upon settlement, and the shares may also be represented by ADSs, with each ADS equal to two ordinary shares.
The filing notes that 5,216 RSUs have already settled. Of the remaining awards, 7,306 RSUs are scheduled to vest in six equal quarterly installments beginning on March 20, 2026. Another 14,244 RSUs are scheduled to vest with 25% on June 20, 2026 and the balance in eight equal quarterly installments, subject to Salovey’s continued service to the company.
Legend Biotech Corp director Casey Patrick John filed an initial ownership report showing existing equity holdings. The filing lists 54,604 Ordinary Shares held directly, including 25,674 restricted share units that vest in scheduled quarterly installments starting on March 20, 2026 and June 20, 2026. It also reports a Share Option for 30,000 Ordinary Shares at an exercise price of 14.1200 per share, expiring on March 28, 2031, which is immediately exercisable. The company notes each ADS represents two Ordinary Shares.
Legend Biotech Corp director Gareth Kung filed an initial ownership report showing 31,486 restricted share units (RSUs). Each RSU represents a contingent right to receive one ordinary share. Twenty-five percent of the RSUs vest on February 2, 2027, with the remainder vesting in eight equal quarterly installments beginning March 20, 2027, subject to continued service. The company’s ordinary shares may also be represented by American Depositary Shares, with each ADS equal to two ordinary shares.
Legend Biotech Corp director Mao Li filed an initial ownership report showing existing equity awards rather than new trades. The filing lists a share option covering 30,000 ordinary shares at an exercise price of 23.2700 per share, expiring on August 1, 2032. Footnotes state 18,000 of these option shares are already exercisable, with the remainder vesting in two equal annual installments starting on August 2, 2026, subject to continued service.
The report also shows direct ownership of 44,330 ordinary shares, including 25,674 restricted share units that convert into one ordinary share each upon settlement. These RSUs vest in multiple quarterly installments beginning on March 20, 2026, and in a larger grant with an initial vest on June 20, 2026 followed by additional quarterly vesting dates. The company notes its ordinary shares may be represented by American Depositary Shares, with each ADS equal to two ordinary shares.
Legend Biotech Corp director Ji Darren Xiaohui reported his initial ownership on a Form 3. He directly holds 63,773 ordinary shares, including 34,662 restricted share units that vest in staged quarterly installments through future dates. He also holds an option immediately exercisable for 30,000 ordinary shares at an exercise price of 11.50, expiring on June 5, 2030. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp director Zhang Fangliang filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not list any specific share or option holdings and shows no recent insider transactions.
Legend Biotech Corp’s Chief Financial Officer, Carlos E. Santos, has filed an initial Form 3 insider ownership statement. The filing identifies him as an officer of the company with the title Chief Financial Officer and does not list any specific transactions in the provided excerpt.
Legend Biotech Corp director Sanders Corazon (Corsee) D. has reported her initial equity holdings in the company. She holds 59,115 ordinary shares directly, which include 25,674 restricted share units that convert into one ordinary share each upon settlement.
She also holds a share option for 12,000 ordinary shares at an exercise price of $11.50 per share, expiring on June 5, 2030, and all of these option shares are immediately exercisable. The restricted share units vest in multiple quarterly installments beginning March 20, 2026 and June 20, 2026, subject to continued service. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp Chief Executive Officer Huang Ying filed an initial ownership report showing direct holdings of 257,374 Ordinary Shares. This total includes 43,010 restricted share units, with 28,119 shares scheduled to vest on March 20, 2026 and 14,891 on June 20, 2026, subject to continued service.
Huang also reports multiple share options over Ordinary Shares at exercise prices from $1.5000 to $27.5000, expiring between July 21, 2029 and April 2, 2033. Footnotes state that some options are immediately exercisable, while others vest on April 3, 2026. Each American Depositary Share represents two Ordinary Shares.